fanaat schreef op 3 december 2021 19:17:
Janssen en janssen.
Pharming is voor de verdere ontwikkeling van OTL-105 deels afhankelijk van Orchard. Dus nog lang niet klaar en afhamkelijk van de kennis van Orchard. Het failliet van Orchard raakt Pharming in het hart en dat zien we allemaal terug in de koersontwikkeling van beide.
Orchard naar $ 1 en minder en Pharming naar de hellepoort .
Under the terms of the collaboration, Pharming has been granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings, and commercialization of the investigational gene therapy, including associated costs. Orchard will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during pre-clinical and clinical development, which will be funded by Pharming. In addition, both companies will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.
Orchard will receive an upfront payment of $17.5 million comprising $10 million in cash and a $7.5 million equity investment from Pharming at a premium to Orchard's recent share price. Orchard is also eligible to receive up to $189.5 million in development, regulatory and sales milestones as well as mid-single to low double-digit royalty payments on future worldwide sales.